Medicine and Dentistry
Epidermolysis bullosa
100%
Quality of Life
24%
Squamous Cell Carcinoma
23%
Psychometry
15%
End of Life Care
14%
Scabies
14%
Permethrin
14%
Benzyl Benzoate
14%
Dermatosis
14%
Cohort Effect
14%
Transcriptome
14%
Patient-Reported Outcome
14%
Proteoglycan
14%
Drug Repositioning
14%
Chronic Disease
14%
Randomized Controlled Trial
14%
DNA RNA Hybridization
14%
RNA Editing
14%
Proteochondroitin Sulfate
14%
Soft Tissue Infection
14%
Diseases
13%
Rare Disease
10%
Clustered Regularly Interspaced Short Palindromic Repeat
10%
Epidermolysis Bullosa Dystrophica
9%
Neoplasm
9%
Genodermatosis
8%
Prevalence
7%
Life Expectancy
7%
Gene Replacement Therapy
7%
Ex Vivo
7%
Tissue Necrosis
7%
Cellulitis
7%
Rapid Assessment
7%
Erysipelas
7%
Dermatoscopy
5%
Pharmacology, Toxicology and Pharmaceutical Science
Epidermolysis bullosa
71%
Squamous Cell Carcinoma
28%
Genodermatosis
17%
microRNA 200b
14%
Epidermolysis Bullosa Dystrophica
14%
Epidermolysis Bullosa Simplex
14%
Clinical Trial
14%
Psoriasis
14%
Proteoglycan
14%
Proteochondroitin Sulfate
14%
Diacerein
14%
Disease
9%
Rare Disease
8%
Blister
7%
Life Expectancy
7%
Prevalence
7%
Neoplasm
6%
Biochemistry, Genetics and Molecular Biology
Epidermolysis bullosa
29%
Genetics
21%
Exon
17%
Myogenesis
14%
Proteoglycan
14%
Antisense
14%
Chondroitin Sulfate Proteoglycan
14%
Oligonucleotide
14%
Intron
11%
Keratin 14
10%
Genetic Screening
9%
Genomics
5%
Basement Membrane
5%
Anchoring Fibrils
5%